About RecombiMAb anti-mouse VEGFR-2 The DC101-CP132 monoclonal antibody is a chimeric version of the original DC101 antibody. The variable domain sequences are identical to the original DC101 but the constant region sequences have been switched from rat IgG1 to mouse IgG2a. The DC101-CP132 antibody contains no Fc mutations just as the original rat IgG1 antibody does not. The DC101-CP132 monoclonal antibody reacts with mouse VEGFR-2 (vascular endothelial growth factor receptor 2) also known as CD309, KDR, and Flk-1. VEGFR-2 is a member of the tyrosine protein kinase family. Upon binding to its ligand VEGF, VEGFR-2 pays key roles in vascular development and permeability. VEGFR-2 is expressed on endothelial cells at high levels in adult heart, lung, kidney, brain, and skeletal muscle as well as other tissues at lower levels. The DC101 antibody has been shown to inhibit VEGFR-2 signaling in vivo. RecombiMAb anti-mouse VEGFR-2 Specifications IsotypeMouse IgG2a, κ Recommended Isotype Control(s)InVivoPlus mouse IgG2a isotype control, unknown specificity Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenMouse VEGFR-2-SEAPs soluble receptor Reported Applicationsin vivo blocking of VEGF/VEGFR-2 signaling* in vitro blocking of VEGFR signaling* Western blot* *Reported for the original rat IgG1 DC101 antibody FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from CHO cell supernatant in an animal-free facility PurificationProtein G Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
